migalastat hydrochloride + agalsidase
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease
Trial Timeline
Sep 8, 2011 → May 28, 2015
NCT ID
NCT01218659About migalastat hydrochloride + agalsidase
migalastat hydrochloride + agalsidase is a phase 3 stage product being developed by Amicus Therapeutics for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01218659. Target conditions include Fabry Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01218659 | Phase 3 | Completed |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 72 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 76 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| agalsidase beta | Sanofi | Approved | 84 |
| Tropicamide | Sanofi | Pre-clinical | 22 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 84 |
| agalsidase beta | Sanofi | Approved | 84 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 84 |
| Gabapentin + placebo | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 76 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 76 |
| Iohexol | Sanofi | Phase 1 | 32 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 84 |